EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

Snegha Ananth iD, Neha Agarwal, Bita Sahaf, Allison Jacob iD, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen-Kai Weng, Melody Smith, Saurabh Dahiya, David Miklos und 1 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Snegha Ananth und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Immunotherapy, Adoptive. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic biomarker in frontline MCL, but its role after CAR T‐cell therapy remains incompletely defined. We retrospectively analyzed 37 patients with r/r MCL treated with brexucabtagene autoleucel (brexu‐cel). MRD was assessed using next‐generation immunoglobulin high‐throughput sequencing (Ig‐HTS) of peripheral blood mononuclear cells obtained before lymphodepletion, at 1‐ and 3‐months post‐infusion, and every 3 months thereafter. Clonotype identification was successful in 36 of 37 patients. Pre‐lymphodepletion MRD levels were lower in patients receiving bridging therapy (337 [0–198 449] vs. 21 213 [1–788 251]; p = 0.04), and MRD undetectability trended toward improved progression‐free survival (PFS; unreached vs. 28.5 months; HR 5.2; p = 0.07). Post‐infusion, patients with detectable Day 28 MRD had inferior PFS compared with those with undetectable MRD (10.9 vs. 51.5 months; HR 3.99; p = 0.002), whereas Day 28 PET‐CT response did not correlate with PFS ( p = 0.35; HR 1.8). Longitudinal MRD monitoring identified relapse a median of 6.5 months before PET/CT in most relapsing patients (15 out of 18). Early and serial MRD monitoring is thus a sensitive prognostic and surveillance tool in brexu‐cel treated MCL, with Day 28 MRD serving as an early predictor of long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellImmunotherapy, AdoptiveHumansNeoplasm, ResidualFemaleRetrospective StudiesMaleRecurrenceAgedMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

immunotherapylymphoid neoplasiameasurable residual disease

Autor:innen und Institutionen

  • Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA.
  • University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Adaptive Biotechnologies, Seattle, Washington, USA.

ORCID-Profile: Snegha Ananth, Allison Jacob

Zitieren

APA

Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., Kirsch, I., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Miklos, D., & Frank, M. J. (2026). Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. American Journal of Hematology. https://doi.org/10.1002/ajh.70343

Vancouver

Ananth S, Agarwal N, Sahaf B, Jacob A, Lee LW, Simmons H, et al. Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. American Journal of Hematology. 2026. doi:10.1002/ajh.70343

BibTeX
@article{Ananth2026,
  author = {Ananth, Snegha and Agarwal, Neha and Sahaf, Bita and Jacob, Allison and Lee, Lik Wee and Simmons, Heidi and Kirsch, Ilan and Bharadwaj, Sushma and Weng, Wen-Kai and Smith, Melody and Dahiya, Saurabh and Miklos, David and Frank, Matthew J},
  title = {Post CAR ‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70343}
}
Kostenlos starten →